GSK’s Bepirovirsen Hits Phase III Targets, Paving Way for First Finite Therapy for Chronic Hepatitis B

An announcement from GlaxoSmithKline ( (GB:GSK) ) is now available.

GSK has reported positive topline data from its pivotal Phase III B-Well 1 and B-Well 2 trials of bepirovirsen, an investigational antisense oligonucleotide being developed as a finite, six‑month treatment for chronic hepatitis B (CHB), a condition affecting more than 250 million people and responsible for over half of global liver cancer cases. The trials, involving more than 1,800 patients across 29 countries, met their primary endpoint, showing statistically significant and clinically meaningful functional cure rates when bepirovirsen was added to current nucleos(t)ide analogue standard of care versus standard care alone, with even greater benefit in patients with lower baseline hepatitis B surface antigen levels and an acceptable safety profile; GSK plans global regulatory filings beginning in early 2026, positioning bepirovirsen as a potential first-in-class finite therapy and backbone for future sequential treatment strategies in hepatitis B, which could strengthen the company’s presence in hepatology and offer a major shift in long-term disease management for patients and healthcare systems.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £16.60 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GB:GSK Stock

According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.

GlaxoSmithKline’s overall stock score is driven by strong financial performance and favorable valuation metrics. The company’s strategic initiatives, including share buybacks and R&D investments, support its growth outlook. However, challenges in cash flow and certain market segments warrant cautious optimism.

To see Spark’s full report on GB:GSK stock, click here.

More about GlaxoSmithKline

GSK is a global biopharmaceutical company that applies science and technology to develop innovative medicines and vaccines, with a stated purpose of getting ahead of disease. The group maintains an expanding hepatology pipeline and focuses on therapies that address significant unmet medical need, including infectious diseases with large global burdens such as chronic hepatitis B.

Average Trading Volume: 8,205,920

Technical Sentiment Signal: Buy

Current Market Cap: £73.44B

For an in-depth examination of GSK stock, go to TipRanks’ Overview page.